Effect of Cisplatin on Parotid Gland Function in Concomitant Radiochemotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 5, 2009, Pages 1475-1480

  Hey, Jeremias ^a   Setz, Jürgen ^a   Gerlach, Reinhard ^b   Vordermark, Dirk ^b   Gernhardt, Christian R ^a   Kuhnt, Thomas ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Chemotherapy; Head and neck cancer; Normal tissue complication probability; Radiation; Saliva

Indexed keywords

CIS-PLATIN; DOSE-VOLUME HISTOGRAMS; HEAD-AND-NECK CANCER; INTENSITY-MODULATED RADIOTHERAPY; NORMAL TISSUE COMPLICATION PROBABILITIES; NORMAL TISSUE COMPLICATION PROBABILITY; NORMAL-TISSUE COMPLICATION PROBABILITY MODELS; PAROTID GLAND FUNCTION; PAROTID GLANDS; PRE-TREATMENT; RADIOCHEMOTHERAPY; RADIOTHERAPY ALONE; RADIOTHERAPY PLANNING; SALIVARY FLOW; TISSUE COMPLICATIONS; TISSUE DAMAGE; VOLUME DISTRIBUTIONS;

BODY FLUIDS; CHEMOTHERAPY; PATIENT MONITORING; PLATINUM COMPOUNDS; PROBABILITY; TISSUE;

RADIOTHERAPY;

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW RATE; HEAD AND NECK CANCER; HISTOGRAM; HUMAN; HYPOSALIVATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PAROTID GLAND DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SALIVATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MOUTH NEOPLASMS; PAROTID GLAND; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL; SALIVATION; TIME FACTORS;

EID: 71649107962     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.071     Document Type: Article

References (31)

1. Lin A., Kim H.M., Terrell J.E., Dawson L.A., et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study. Int J Radiat Oncol Biol Phys 57 (2003) 61-70
2. Romaniuk K., Gavin J.B., and Adkins K.F. The effect of methotrexate on salivary glands in the rat. J Dent Res 62 (1983) 678
3. Lockhart P.B., and Sonis S.T. Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J Dermatol Surg Oncol 7 (1981) 1019-1025
4. Kosuda S., Satoh M., Yamamoto F., Uematsu M., and Kusano S. Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys 45 (1999) 379-384
5. Harrison T., Bigler L., Tucci M., et al. Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: An exploratory study. Spec Care Dentist 18 (1998) 109-112
6. Tomita Y., and Osaki T. Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment. Int J Oral Maxillofac Surg 19 (1990) 299-304
7. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
8. Glicksman A.S., Wanebo H.J., Slotman G., et al. Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 39 (1997) 721-729
9. Altundag O., Altundag K., Morandi P., and Hanrahan E. Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer. Oral Oncol 41 (2005) 435
10. Bernier J., Vermorken J.B., and Koch W.M. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 24 (2006) 2629-2635
11. Epstein J.B., Tsang A.H., Warkentin D., and Ship J.A. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: A review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 (2002) 39-44
12. Jensen S.B., Pedersen A.M., Reibel J., and Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11 (2003) 207-225
13. Scully C. Drug effects on salivary glands: Dry mouth. Oral Dis 9 (2003) 165-176
14. Kuhnt T., Janich M., Gotz U., et al. [Presentation of a 3D conformal radiotherapy technique for head-and-neck tumors resulting in substantial protection of the parotid glands]. Strahlenther Onkol 182 (2006) 325-330
15. Marmiroli L., Salvi G., Caiazza A., Di Rienzo L., Massaccesi M., Murino P., et al. Dose and volume impact on radiation-induced xerostomia. Rays 30 (2005) 145-148
16. Roesink J.M., Moerland M.A., Battermann J.J., Hordijk G.J., and Terhaard C.H. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys 51 (2001) 938-946
17. Burlage F.R., Roesink J.M., Kampinga H.H., Coppes R.P., Terhaard C., Langendijk J.A., et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: A double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 70 (2008) 14-22
18. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8 (1985) S13-S19
19. Semenenko V.A., and Li X.A. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol 53 (2008) 737-755
20. Tucker S.L., Dong L., Cheung R., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1589-1601
21. Yamamoto T., Staples J., Wataha J., et al. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride. Anticancer Res 24 (2004) 3065-3073
22. Marcu L., van Doorn T., and Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-a review of their cooperation. Acta Oncol 42 (2003) 315-325
23. Kim S.W., Lee J.U., Nah M.Y., et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 12 (2001) 875-882
24. Delporte C., and Steinfeld S. Distribution and roles of aquaporins in salivary glands. Biochim Biophys Acta 1758 (2006) 1061-1070
25. Shan Z., Li J., Zheng C., Liu X., et al. Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Mol Ther 11 (2005) 444-451
26. Takagi K., Yamaguchi K., Sakurai T., et al. Secretion of saliva in X-irradiated rat submandibular glands. Radiat Res 159 (2003) 351-360
27. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
28. Dijkema T., Raaijmakers C.P.J., Ten Haken R.K., et al. Parotid Gland Function after Radiotherapy: The Combined Michigan and Utrecht Experience. Int J Radiat Oncol Biol Phys 72 (2008) 1-9
29. Bardow A., Moe D., Nyvad B., and Nauntofte B. The buffer capacity and buffer systems of human whole saliva measured without loss of CO2. Arch Oral Biol 45 (2000) 1-12
30. Konings A.W., Cotteleer F., Faber H., et al. Volume effects and region-dependent radiosensitivity of the parotid gland. Int J Radiat Oncol Biol Phys 62 (2005) 1090-1095
31. Gregoire V. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer. Rays 30 (2005) 105-108